Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Richard Daniell sold 1,297 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $17.89, for a total transaction of $23,203.33. Following the sale, the vice president now directly owns 1,297 shares in the company, valued at approximately $23,203.33. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Richard Daniell also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 5th, Richard Daniell sold 1,108 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $19.28, for a total transaction of $21,362.24.

Teva Pharmaceutical Industries stock traded down $0.27 on Thursday, hitting $17.33. 2,994,790 shares of the stock traded hands, compared to its average volume of 16,806,057. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $33.82. The stock has a market capitalization of $17,978.39, a PE ratio of -1.07, a price-to-earnings-growth ratio of 1.54 and a beta of 0.65.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the company earned $1.38 earnings per share. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. equities analysts predict that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current year.

TEVA has been the topic of a number of research reports. Goldman Sachs lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, January 11th. Morgan Stanley raised shares of Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price target for the company in a research report on Friday, December 15th. Royal Bank of Canada set a $11.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Finally, Susquehanna Bancshares reissued a “positive” rating and set a $24.00 price target (up from $22.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, January 25th. Ten equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $20.69.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Calton & Associates Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $108,000. Fieldpoint Private Securities LLC bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at approximately $171,000. Global Financial Private Capital LLC bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $193,000. Wetherby Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $197,000. Finally, Sigma Planning Corp bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $214,000. 58.19% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/richard-daniell-sells-1297-shares-of-teva-pharmaceutical-industries-ltd-teva-stock/1956756.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.